Their results showed that the effects of the GLP-1 RA liraglutide were independent of the MC4R pathway, suggesting that this could represent a therapeutic opportunity for patients with various forms of monogenic obesity, especially for those with MC4R mutation [52]. Here, MC4R is linked to Obesity.